secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2026-08-07T11:00:11+00:00
Accession:  0001023024-26-000068
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma Q2 revenue $266M (+25.9%), GAAP EPS $1.05, adjusted EPS $2.21
------------------------------------------------------------------------

- Q2 net revenue $266.0M, +25.9% YoY; GAAP net income $24.7M ($1.05/diluted) vs $8.1M prior year.
- Cortrophin Gel revenue $117.1M, +43.5% YoY; ILUVIEN down 16.1% to $18.7M on shipment timing.
- Adjusted non-GAAP EBITDA $71.6M (+32.4%); adjusted diluted EPS $2.21 vs $1.80 prior.
- FY26 total revenue guidance reaffirmed $1,080-1,140M; Cortrophin Gel guidance narrowed to $520-540M from $540-575M.
- Board authorized $100M share repurchase program through May 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/0001023024-26-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/ani-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001023024-26-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer